Bellevue Group AG Acquires 72,437 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Bellevue Group AG grew its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 13.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 629,758 shares of the company’s stock after buying an additional 72,437 shares during the quarter. Bellevue Group AG’s holdings in Structure Therapeutics were worth $27,640,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Sandia Investment Management LP purchased a new position in Structure Therapeutics during the second quarter valued at approximately $39,000. Assetmark Inc. increased its holdings in shares of Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after acquiring an additional 719 shares during the period. Quarry LP bought a new position in shares of Structure Therapeutics in the 2nd quarter worth $79,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after acquiring an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC purchased a new stake in shares of Structure Therapeutics during the 3rd quarter worth $202,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on GPCR shares. JMP Securities cut their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research note on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, Morgan Stanley initiated coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $86.80.

Structure Therapeutics Trading Down 1.8 %

Structure Therapeutics stock opened at $33.15 on Friday. Structure Therapeutics Inc. has a one year low of $26.61 and a one year high of $66.38. The stock has a 50-day moving average of $38.21 and a two-hundred day moving average of $39.43.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.